MIM
IMMX icon

MetLife Investment Management’s Immix Biopharma IMMX Stock Holding History

MetLife Investment Management’s Portfolio IMMX Stock Details IMMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$257K Buy
+24,932
New +$231K ﹤0.01% 2293

Other funds holding IMMX

JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

MetLife Investment Management's IMMX Position: Q2 2026 in Review

MetLife Investment Management opened a new position in Immix Biopharma (IMMX) in Q2 2026: 24,932 shares worth $257K. The stake represents ﹤0.01% of the portfolio and ranks #2293 among its holdings.

109 funds tracked by Wall St. Rank hold IMMX as of Q2 2026.

  • MetLife Investment Management held 24,932 shares of Immix Biopharma worth $257K as of Q2 2026.
  • Immix Biopharma was a new MetLife Investment Management position in Q2 2026.
  • Immix Biopharma made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #2293 holding.
  • 109 funds tracked by Wall St. Rank held Immix Biopharma as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.